Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study.

PLoS One · 2015 · PMC4567072 · PMID 26360583

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

In the DAS28-remission-Modified dataset (trials categorized as “DMARD-naïve” were omitted in the modified datasets), this trial eligibility criterion showed significant interaction among subgroups and it was borderline significant in the ACR20-Modified dataset.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.